Oleoylethanolamide and Palmitoylethanolamide Enhance IFNβ-Induced Apoptosis in Human Neuroblastoma SH-SY5Y Cells

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2024 Apr 13

PMID 38611871

Authors

Chiara Camoglio

Jihane Balla

Paola Fadda

Simona Dedoni

Affiliations

Soon will be listed here.

Abstract

Oleoylethanolamide (OEA) and palmitoylethanolamide (PEA) are endogenous lipids that act as agonists of the peroxisome proliferator-activated receptor α (PPARα). Recently, an interest in the role of these lipids in malignant tumors has emerged. Nevertheless, the effects of OEA and PEA on human neuroblastoma cells are still not documented. Type I interferons (IFNs) are immunomodulatory cytokines endowed with antiviral and anti-proliferative actions and are used in the treatment of various pathologies such as different cancer forms (i.e., non-Hodgkin's lymphoma, melanoma, leukemia), hepatitis B, hepatitis C, multiple sclerosis, and many others. In this study, we investigated the effect of OEA and PEA on human neuroblastoma SH-SY5Y cells treated with IFNβ. We focused on evaluating cell viability, cell proliferation, and cell signaling. Co-exposure to either OEA or PEA along with IFNβ leads to increased apoptotic cell death marked by the cleavage of caspase 3 and poly-(ADP ribose) polymerase (PARP) alongside a decrease in survivin and IKBα levels. Moreover, we found that OEA and PEA did not affect IFNβ signaling through the JAK-STAT pathway and the STAT1-inducible protein kinase R (PKR). OEA and PEA also increased the phosphorylation of p38 MAP kinase and programmed death-ligand 1 (PD-L1) expression both in full cell lysate and surface membranes. Furthermore, GW6471, a PPARα inhibitor, and the genetic silencing of the receptor were shown to lower PD-L1 and cleaved PARP levels. These results reveal the presence of a novel mechanism, independent of the IFNβ-prompted pathway, by which OEA and PEA can directly impair cell survival, proliferation, and clonogenicity through modulating and potentiating the intrinsic apoptotic pathway in human SH-SY5Y cells.

References

Butler L, Perone Y, Dehairs J, Lupien L, de Laat V, Talebi A . Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention. Adv Drug Deliv Rev. 2020; 159:245-293. PMC: 7736102. DOI: 10.1016/j.addr.2020.07.013. View

Dedoni S, Marras L, Olianas M, Ingianni A, Onali P . Valproic acid upregulates the expression of the p75NTR/sortilin receptor complex to induce neuronal apoptosis. Apoptosis. 2020; 25(9-10):697-714. PMC: 7527367. DOI: 10.1007/s10495-020-01626-0. View

Gandini S, Massi D, Mandala M . PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2016; 100:88-98. DOI: 10.1016/j.critrevonc.2016.02.001. View

Hovanessian A, La Bonnardiere C, FALCOFF E . Action of murine gamma (immune)interferon on beta (fibroblast)-interferon resistant L 1210 and embryonal carcinoma cells. J Interferon Res. 1980; 1(1):125-35. DOI: 10.1089/jir.1980.1.125. View

Dedoni S, Olianas M, Ingianni A, Onali P . Type I interferons up-regulate the expression and signalling of p75 NTR/TrkA receptor complex in differentiated human SH-SY5Y neuroblastoma cells. Neuropharmacology. 2013; 79:321-34. DOI: 10.1016/j.neuropharm.2013.12.002. View

Tutunchi H, Saghafi-Asl M, Ostadrahimi A . A systematic review of the effects of oleoylethanolamide, a high-affinity endogenous ligand of PPAR-α, on the management and prevention of obesity. Clin Exp Pharmacol Physiol. 2019; 47(4):543-552. DOI: 10.1111/1440-1681.13238. View

Yamagata K, Uzu E, Yoshigai Y, Kato C, Tagami M . Oleic acid and oleoylethanolamide decrease interferon-γ-induced expression of PD-L1 and induce apoptosis in human lung carcinoma cells. Eur J Pharmacol. 2021; 903:174116. DOI: 10.1016/j.ejphar.2021.174116. View

Dedoni S, Olianas M, Onali P . Interferon-β induces apoptosis in human SH-SY5Y neuroblastoma cells through activation of JAK-STAT signaling and down-regulation of PI3K/Akt pathway. J Neurochem. 2010; 115(6):1421-33. DOI: 10.1111/j.1471-4159.2010.07046.x. View

Nissen S, Nicholls S, Wolski K, Howey D, McErlean E, Wang M . Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. JAMA. 2007; 297(12):1362-73. DOI: 10.1001/jama.297.12.1362. View

10.

Hamtiaux L, Masquelier J, Muccioli G, Bouzin C, Feron O, Gallez B . The association of N-palmitoylethanolamine with the FAAH inhibitor URB597 impairs melanoma growth through a supra-additive action. BMC Cancer. 2012; 12:92. PMC: 3364151. DOI: 10.1186/1471-2407-12-92. View

11.

Borden E, Sen G, Uze G, Silverman R, Ransohoff R, Foster G . Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov. 2007; 6(12):975-90. PMC: 7097588. DOI: 10.1038/nrd2422. View

12.

Rakhshandehroo M, Knoch B, Muller M, Kersten S . Peroxisome proliferator-activated receptor alpha target genes. PPAR Res. 2010; 2010. PMC: 2948931. DOI: 10.1155/2010/612089. View

13.

Lefebvre P, Chinetti G, Fruchart J, Staels B . Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest. 2006; 116(3):571-80. PMC: 1386122. DOI: 10.1172/JCI27989. View

14.

Schreiner B, Mitsdoerffer M, Kieseier B, Chen L, Hartung H, Weller M . Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. J Neuroimmunol. 2004; 155(1-2):172-82. DOI: 10.1016/j.jneuroim.2004.06.013. View

15.

Dedoni S, Marras L, Olianas M, Ingianni A, Onali P . Downregulation of TrkB Expression and Signaling by Valproic Acid and Other Histone Deacetylase Inhibitors. J Pharmacol Exp Ther. 2019; 370(3):490-503. DOI: 10.1124/jpet.119.258129. View

16.

Sadler A, Williams B . Interferon-inducible antiviral effectors. Nat Rev Immunol. 2008; 8(7):559-68. PMC: 2522268. DOI: 10.1038/nri2314. View

17.

Kotredes K, Gamero A . Interferons as inducers of apoptosis in malignant cells. J Interferon Cytokine Res. 2013; 33(4):162-70. PMC: 3624694. DOI: 10.1089/jir.2012.0110. View

18.

Pagano E, Venneri T, Lucariello G, Cicia D, Brancaleone V, Nani M . Palmitoylethanolamide Reduces Colon Cancer Cell Proliferation and Migration, Influences Tumor Cell Cycle and Exerts In Vivo Chemopreventive Effects. Cancers (Basel). 2021; 13(8). PMC: 8073478. DOI: 10.3390/cancers13081923. View

19.

Hamtiaux L, Hansoulle L, Dauguet N, Muccioli G, Gallez B, Lambert D . Increasing antiproliferative properties of endocannabinoids in N1E-115 neuroblastoma cells through inhibition of their metabolism. PLoS One. 2011; 6(10):e26823. PMC: 3203169. DOI: 10.1371/journal.pone.0026823. View

20.

Allagnat F, Cunha D, Moore F, Vanderwinden J, Eizirik D, Cardozo A . Mcl-1 downregulation by pro-inflammatory cytokines and palmitate is an early event contributing to β-cell apoptosis. Cell Death Differ. 2010; 18(2):328-37. PMC: 3131897. DOI: 10.1038/cdd.2010.105. View